ATYR vs. NUTX
ATYR (aTyr Pharma, Inc.) and NUTX (Nutex Health Inc) are both stocks. Both are in the Healthcare sector — ATYR in Biotechnology, NUTX in Health Information Services. Over the past 3 years, ATYR returned -40.12%/yr vs 30.28%/yr for NUTX. At a 0.15 correlation, their price movements are largely independent.
Performance
ATYR vs. NUTX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ATYR achieves a -39.96% return, which is significantly lower than NUTX's -8.78% return.
ATYR
- 1D
- 4.37%
- 1M
- -4.04%
- YTD
- -39.96%
- 6M
- -35.23%
- 1Y
- -90.99%
- 3Y*
- -40.12%
- 5Y*
- -36.40%
- 10Y*
- -35.88%
NUTX
- 1D
- -0.23%
- 1M
- 26.29%
- YTD
- -8.78%
- 6M
- -16.36%
- 1Y
- 31.86%
- 3Y*
- 30.28%
- 5Y*
- —
- 10Y*
- —
ATYR vs. NUTX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
ATYR aTyr Pharma, Inc. | -39.96% | -78.37% | 156.74% | -35.62% | -60.82% |
NUTX Nutex Health Inc | -8.78% | 419.47% | 17.37% | -90.53% | -81.82% |
Correlation
The correlation between ATYR and NUTX is 0.04, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.04 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.10 |
Correlation (All Time) Calculated using the full available price history since Apr 4, 2022 | 0.15 |
The correlation between ATYR and NUTX shifts across timeframes, from 0.04 (1 year) to 0.15 (all time), reflecting how their relationship changes across market environments.
Fundamentals
ATYR:
-$0.73
NUTX:
$19.08
ATYR:
237.16
NUTX:
0.86
ATYR:
$190.00K
NUTX:
$879.95M
ATYR:
-$22.33M
NUTX:
$417.67M
ATYR:
-$71.35M
NUTX:
$275.94M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ATYR vs. NUTX — Risk / Return Rank
ATYR
NUTX
ATYR vs. NUTX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for aTyr Pharma, Inc. (ATYR) and Nutex Health Inc (NUTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ATYR | NUTX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.00 | ||
| Sortino ratioReturn per unit of downside risk | -1.86 | ||
| Omega ratioGain probability vs. loss probability | 0.87 | 1.14 | -0.27 |
| Calmar ratioReturn relative to maximum drawdown | -0.97 | 0.59 | -1.56 |
| Martin ratioReturn relative to average drawdown | -1.17 | 1.03 | -2.20 |
Loading charts...
Drawdowns
ATYR vs. NUTX - Drawdown Comparison
The maximum ATYR drawdown since its inception was -99.90%, roughly equal to the maximum NUTX drawdown of -99.93%. Use the drawdown chart below to compare losses from any high point for ATYR and NUTX.
Loading charts...
Drawdown Indicators
| ATYR | NUTX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.90% | -99.93% | +0.03% |
Max Drawdown (1Y)Largest decline over 1 year | -94.01% | -54.32% | -39.69% |
Max Drawdown (3Y)Largest decline over 3 years | -94.01% | -93.95% | -0.06% |
Max Drawdown (5Y)Largest decline over 5 years | -96.83% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -99.55% | — | — |
Current DrawdownCurrent decline from peak | -99.88% | -97.50% | -2.38% |
Average DrawdownAverage peak-to-trough decline | -93.17% | -97.18% | +4.01% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 77.49% | 31.02% | +46.47% |
Volatility
ATYR vs. NUTX - Volatility Comparison
aTyr Pharma, Inc. (ATYR) has a higher volatility of 21.70% compared to Nutex Health Inc (NUTX) at 16.28%. This indicates that ATYR's price experiences larger fluctuations and is considered to be riskier than NUTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ATYR | NUTX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 21.70% | 16.28% | +5.42% |
Volatility (6M)Calculated over the trailing 6-month period | 95.12% | 62.51% | +32.61% |
Volatility (1Y)Calculated over the trailing 1-year period | 139.96% | 93.38% | +46.58% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 89.87% | 191.46% | -101.59% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 88.44% | 191.46% | -103.02% |
Dividends
ATYR vs. NUTX - Dividend Comparison
Neither ATYR nor NUTX has paid dividends to shareholders.
Financials
ATYR vs. NUTX - Financials Comparison
This section allows you to compare key financial metrics between aTyr Pharma, Inc. and Nutex Health Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ATYR and NUTX have a correlation of 0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ATYR has higher volatility (21.70%) compared to NUTX (16.28%). In terms of maximum drawdown, ATYR dropped -99.90% vs NUTX's -99.93%.
NUTX currently has the higher Sharpe Ratio (0.34 vs -0.65), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ATYR and NUTX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer